PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes

Modern Pathology

Volumn 29, Issue 9, 2016, Pages 1104-1112

  Rosenbaum, Matthew W ^a   Bledsoe, Jacob R ^a   Morales Oyarvide, Vicente ^a   Huynh, Tiffany G ^a   Mino Kenudson, Mari ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; B RAF KINASE; CD8 ANTIGEN; K RAS PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; BRAF PROTEIN, HUMAN; CD274 PROTEIN, HUMAN; TUMOR MARKER;

ADAPTIVE IMMUNITY; ADULT; AGE; AGED; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COLON CARCINOGENESIS; COLORECTAL CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; DISEASE SPECIFIC SURVIVAL; FEMALE; GENE FREQUENCY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE EVASION; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; SURVIVAL PREDICTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR DIFFERENTIATION; TUMOR IMMUNITY; CHI SQUARE DISTRIBUTION; COLORECTAL TUMOR; CYTOTOXIC T LYMPHOCYTE; DNA MUTATIONAL ANALYSIS; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MUTATION; ODDS RATIO; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICAL MODEL; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; TUMOR VOLUME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM STAGING; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; RISK FACTORS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR BURDEN; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; YOUNG ADULT;

EID: 84969610700     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.95     Document Type: Conference Paper

References (28)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12: 252-264.
2. Hino R, Kabashima K, Kato Y et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010;116:1757-1766.
3. Wu P, Wu D, Li L et al. PD-L1 and survival in solid tumors: a meta-analysis. PLoS One 2015;10:e0131403.
4. Droeser RA, Hirt C, Viehl CT et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013;49:2233-2242.
5. Song M, Chen D, Lu B et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One 2013;8:e65821.
6. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-2465.
7. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454.
8. Topalian SL, Sznol M, McDermott DF et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-1030.
9. Llosa NJ, Cruise M, Tam A et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015;5:43-51.
10. Le DT, Uram JN, Wang H et al. PD-1 in tumors with mismatch-repair deficiency. N Engl J Med 2015;372: 2509-2520.
11. Dias-Santagata D, Akhavanfard S, David SS et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol MEd 2010;2:146-158.
12. Ostrand-Rosenberg S, Horn LA, Haile ST. The programmed death-1 immune-supressive pathway: barrier to antitumor immunity. J Immunol 2014;193:3835-3841.
13. Rooney MS, Shukla SA, Wu CJ et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015;160:48-61.
14. O'Brien MJ, Zhao Q, Yang S. Colorectal serrated pathway cancers and precursors. Histopathology 2015;66:49-65.
15. Akbay EA, Koyama S, Carretero J et al. Activation of the PD-1 pathway contributes to immune escape in EGFRdriven lung tumors. Cancer Discov 2013;3:1355-1363.
16. Ota K, Azuma K, Kawahara A et al. Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer. Clin Cancer Res 2015;21:4014-4021.
17. Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov 2015;5: 915-919.
18. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-1034.
19. Taube JM, Klein A, Brahmer JR et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20:5064-5074.
20. Vaughn CP, Zobell SD, Furtado LV et al. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 2011; 50:307-312.
21. Huynh T, Oyarvide-Morales V, Uruga H et al. Clinicopathological and molecular parameters of lung adenocarcinomas (ADC) associated with programmed cell death ligand 1 (PD-1L) protein expression. J Clin Oncol 2015;33:abstr 7554.
22. Rizvi NA, Hellmann MD, Snyder A et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-128.
23. Sholl LM, Aisner DL, Allen TC et al. Programmed death ligand 1 immunohistochemistry-A new challenge for pathologists: a perspective from members of the pulmonary pathology society. Arch Pathol Lab Med 2016;140:341-344.
24. Kim MY, Koh J, Kim S et al. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumorinfiltrating T cells and the status of oncogenic drivers. Lung Cancer 2015;88:24-33.
25. Koh J, Go H, Keam B et al. Clinicopathologic analysis of programmed cell death-1 and programmed cell deathligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. Mod Pathol 2015;28:1154-1166.
26. Tang Y, Fang W, Zhang Y et al. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget 2015;6: 14209-14219.
27. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-1639.
28. Ilie M, Long-Mira E, Bence C et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 2016;27: 147-153.